Ishihara Sangyo Kaisha, Ltd.

Shiga University of Medical Science

Masanari Kato

Nobutoshi Yamada

Keizo Miyata

Yoshiyuki Aoyama

Hiroshi Shikama

Takashi Okada

Hirohiko Kimura

Shigehiro Morikawa

Makoto Urushitani

Koichi Hirao

Ikuo Tooyama

Daijiro Yanagisawa

Tomone Nagae

Hiroyasu Taguchi

Nobuaki Shirai

Disclosed are a curcumin derivative or a salt thereof, which contains a fluorine atom, represented by formula (I): (wherein Rand Rare each independently a hydrogen atom, alkyl, acetyl, or methoxycarbonyl; Rs are each independently a fluorine atom, CHF&#x2014;, CF&#x2014;, CHFO&#x2014;, or CFO&#x2014;; Rs are each independently a hydrogen atom or a fluorine atom; A is alkyl, cyano, carboxyl, alkoxycarbonyl, or R&#x2014;(CH)&#x2014;; Ris hydroxy, carboxy, cyano, acetyloxy, alkoxycarbonyl, alkoxyalkoxy, hydroxyalkoxy, or CONRR; Rand Rare each independently a hydrogen atom or alkyl; and m is an integer from 1 to 5), and a diagnostic imaging agent for diagnosing a disease in which an amyloid &#x3b2; peptide aggregate accumulates, the diagnostic imaging agent containing a compound having a 1,3-dicarbonyl structure, wherein the compound exists in a keto form and an enol form, and the keto form and the enol form have different affinities, respectively, to the amyloid &#x3b2; peptide aggregate.

Imaging diagnostic agent and extracorporeal diagnostic agent for incurable neurological diseases

A polypeptide which is a tumor necrosis factor polypeptide having an amino acid sequence represented by from the 1st Ser to the 155th Leu as shown by SEQ ID NO:1 in the Sequence Listing, or its mutein, wherein the amino acid sequence of the 1st Ser to the 8th Asp of the SEQ ID NO:1 or the corresponding amino acid sequence of the mutein is replaced by an amino acid sequence containing at least one amino acid sequence of Arg-Gly-Asp and from 3 to 16 amino acids. Also disclosed are a recombinant plasmid containing a DNA encoding such a polypeptide, a recombinant microbial cell transformed by such a recombinant plasmid, a process for producing the polypeptide, a pharmaceutical composition comprising the polypeptide as an active ingredient, and a DNA for the polypeptide.

Muteins of TNF pharmaceutical compositions and a method of making

A polypeptide which is a tumor necrosis factor polypeptide having an amino acid sequence represented by from the 1st Ser to the 155th Leu as shown by SEQ ID NO:1 in the Sequence Listing, or its mutein, wherein the amino acid sequence of the 1st Ser to the 8th Asp of the SEQ ID NO:1 or the corresponding amino acid sequence of the mutein is replaced by an amino acid sequence containing at least one amino acid sequence of cell-adherent peptide of laminin and from 5 to 30 amino acids. Also disclosed are a recombinant plasmid containing a DNA encoding such a polypeptide, a recombinant microbial cell transformed by such a recombinant plasmid, a process for producing the polypeptide, a pharmaceutical composition comprising the polypeptide as an active ingredient, and a DNA for the polypeptide.

N-terminal muteins of tumor necrosis factor

Growing community of inventors

Kusatsu, Japan

Masanari Kato